

New number of shares and votes in Q-linea AB (publ)

The number of shares and votes in Q-linea AB (publ) (the “Company”) has increased during February as a result of the rights issue of units resolved by the board of directors on November 5, 2024, with subsequent approval by the extraordinary general meeting on December 6, 2024, and the directed issue of 129,522,730 units resolved by the board of directors on February 10, 2025, with authorization.

As of February 28, 2025, the total number of shares in the Company amounts to 4,005,200,236 shares (previously 117,166,372 shares), with one vote each. All shares are common shares. The share capital amounts to SEK 200,260,011.80 (previously SEK 5,858,318.60). As of February 28, 2025, Q-linea AB holds 328,472 of its own shares.

Please note that the issues have been partially registered and the remaining 443,087,860 shares in the rights issue and the directed issue have not yet been registered and are therefore not included in this announcement. The remaining shares are subscribed by Ulf Landegren, through Landegren Gene Technology AB, are subject to notification to ISP. After the investment is left without action or approved by ISP, the number of shares in Q-linea will increase by 443,087,860, whereby the number of outstanding shares in Q-linea will amount to 4,448,288,096.

For more information, please contact:

Stuart Gander, President & CEO, Q-linea
Stuart.Gander@qlinea.com
+1 857 409 7463

Christer Samuelsson, CFO /IR, Q-linea AB
Christer.Samuelsson@qlinea.com
+46 (0) 70-600 15 20

About Q-linea

Q-linea’s rapid AST system, ASTar[®], accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner — when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.

Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.

ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit www.qlinea.com

This information is information that Q-linea is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2025-02-28 08:30 CET.

Attachments

[New number of shares and votes in Q-linea AB \(publ\)](#)